More than 160,000 Australians per year will benefit from subsidised access to 48 medicines, including treatments for serious heart conditions and rare but serious infections like tuberculosis, and cancer.
These listings include drugs that were deferred in February and new drugs recently considered and approved for listing by Cabinet.
New listings on the PBS and price changes
Most listings will take effect from 1 December 2011, subject to final listing arrangements being met by the suppliers of these medicines and will include:
- paliperadone palmitate (Invega Sustenna®) - for the treatment of schizophrenia
- oxycodone/naloxone (Targin®) - for the treatment of severe cancer pain
- budesonide with eformoterol (Symbicort®) - for the treatment of lung disease
- botulinum toxin type A (Botox®) extension - for the treatment of severe axillary hyperhidrosis
- dalteparin sodium (Fragmin®) - for the treatment of blood clots in patients with cancer
- nafarelin (Synarel®) - for the treatment of patients undergoing in-vitro fertilisation
- alendronate (Fosamax®) - for the treatment of osteoporosis
- asenapine (Saphris®)- for the treatment of bipolar 1 disorder and schizophrenia
- bortezomib (Velcade®)- for the treatment of multiple myeloma in patients with severe acute renal failure
- capecitabine (Xeloda®)- for the treatment of patients with advanced bowel cancer
- darunavir (Prezista®)- for the treatment of HIV infection
- denosumab (Xgeva®)- for the treatment of bone metastases from breast cancer and hormone-resistant prostate cancer
- losartan (Cozavan®) - for the treatment of hypertension
- magnesium aspartate (Mag-Sup®) - for the treatment of hypomagnesaemia and chronic renal disease in Aboriginal and Torres Strait Islander persons
- rituximab (Mabthera®)- a high cost medicine for the treatment of a specific form of chronic lymphocytic leukaemia.
The Government has also agreed to increase the price of 23 medicines currently listed on the PBS including:
- digoxin oral solution (Lanoxin®) - for the treatment of serious heart conditions including heart failure in infants and children
- dothiepin (Dothep®) - for the treatment of depression
- oxprenolol (Corbeton®) - for the treatment of high blood pressure, particularly in pregnancy
- rifampicin (Rimycin®) - for the treatment of rare but serious infections including tuberculosis and as a prophylaxis for close contacts of patients with meningococcal disease
- ritonavir (Norvir®) - for the treatment of HIV infection
- erythromycin lactobionate (Erythrocin-IV®) and erythromycin ethyl succinate (E-Mycin 200®, E.E.S. 200®, E-Mycin 400® and E.E.S. Granules®) - for the treatment of bacterial infections
- acarbose (Glucobay®) - for the treatment of diabetes
- Glucose indicator - urine (Diastix®) – used by diabetes patients
- Hexamine hippurate (Hiprex®) - for the treatment of bacterial infections
- Pancreatic extract (Creon 10,000®, Creon 25,000® and Creon 40,000®) - for the treatment of enzyme deficiency in children and adults
- Sucralfate (Ulcyte® and Carafate®) - for the treatment of peptic ulcers.
Read the Government's media release here